NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. The Board’s d ...

Group 1 - Nexans has announced a share buyback program, detailing purchases of its own shares from January 5, 2026, to January 9, 2026 [1] - The total volume of shares purchased during this period is 8,525 shares [2] - The average purchase prices for the shares varied, with the highest being €131.500000 and the lowest at €125.086921 [2][3] Group 2 - The trades were executed by an investment firm under a mandate, in accordance with the buyback program published on March 27, 2025 [1] - The transactions were conducted on the XPAR market, indicating active trading in Nexans shares [2][3] - Specific daily transactions included purchases of 1,705 shares each day, with varying average prices reflecting market fluctuations [2][3]

Core Viewpoint - Trifork Group AG has initiated a share buyback program, which is set to run from December 23, 2025, to February 26, 2026, with a total budget of DKK 14.92 million (approximately EUR 2 million) [1][2]. Group 1: Share Buyback Program Details - The share buyback program allows Trifork to purchase shares totaling up to DKK 14.92 million, with prior holdings of 219,735 treasury shares, representing 1.1% of the share capital [2]. - As of January 9, 2026, a total of 35,220 shares have been repurchased at an average price of DKK 92.59, amounting to DKK 3,261,114 [2][3]. - The transactions conducted under the program include purchases on January 5, 6, 7, 8, and 9, 2026, with varying average purchase prices [2]. Group 2: Impact on Treasury Shares - On January 5, 2026, 33,587 shares from the buyback were utilized for the RSU plan for certain employees, resulting in a total of 221,368 treasury shares held by Trifork, still corresponding to 1.1% of the share capital [4]. - The total number of registered shares in Trifork is 19,744,899, leading to 19,523,531 outstanding shares after adjusting for treasury shares [4]. Group 3: Company Overview - Trifork is a global technology company specializing in innovative digital products and solutions for enterprise and public sector customers, with a workforce of 1,197 employees across 16 countries [5]. - The company focuses on advanced software development in sectors such as public administration, healthcare, financial services, energy, and aviation, with its R&D arm, Trifork Labs, driving innovation [5].

Core Viewpoint - Truecaller AB has been actively repurchasing its own B shares as part of a buyback program initiated in May 2025, with a total of 1,603,541 shares repurchased during the week of January 5-9, 2026, representing 0.45% of outstanding capital [1][2]. Share Buyback Program - The buyback program allows Truecaller to repurchase shares until the Annual General Meeting (AGM) in May 2026, with the total repurchased shares since the program's inception reaching 8,644,594, or 2.44% of outstanding capital [1][2]. - The Board was authorized to buy back B-shares up to a limit of 10% of the total number of outstanding shares as of the AGM date [2]. Weekly Buyback Details - During the week of January 5-9, 2026, the daily aggregated volume of shares repurchased was as follows: - January 5: 150,000 shares at an average price of SEK 18.52 - January 6: 850,000 shares at an average price of SEK 17.98 - January 7: 503,541 shares at an average price of SEK 17.91 - January 8: 100,000 shares at an average price of SEK 18.16 - The total transaction value for the week amounted to SEK 28,891,804 [3]. Total Holdings and Outstanding Shares - As of January 9, 2026, Truecaller holds a total of 12,589,926 B shares and 5,013,786 C shares, which corresponds to 4.98% of the outstanding capital [4]. - The total number of shares in Truecaller, including its own shares, is now 353,790,721, while the number of outstanding shares, excluding own shares, is 336,187,009 [4]. Historical Buyback Summary - A summary of Truecaller's buyback programs shows the following: - October 2022 - May 2023: 281,779 shares at an average price of SEK 33.99, total value SEK 451,447,668 - June 2023 - May 2024: 365,336 shares at an average price of SEK 31.78, total value SEK 488,310,378 - June 2024 - May 2025: 945,332 shares at an average price of SEK 36.35, total value SEK 143,397,037 - June 2025 - present: 8,644,593 shares at an average price of SEK 26.47, total value SEK 228,786,009 - The total accumulated buybacks amount to 41,237,041 shares at an average price of SEK 31.81, with a total transaction value of SEK 1,311,941,092 [5].

Core Viewpoint - Aegon has initiated a EUR 227 million share buyback program, which includes EUR 200 million from a previously announced buyback, with an additional EUR 27 million allocated for share-based compensation obligations for senior management [1][2]. Group 1: Share Buyback Details - The share buyback program is set to be completed by June 30, 2026, unless unforeseen circumstances arise [1]. - Aegon's largest shareholder, Vereniging Aegon, will participate in the buyback, contributing EUR 37 million, which is approximately 18.4% of the total voting rights [2]. - Aegon will engage a third party to execute the buyback transactions, repurchasing shares at a maximum of the average daily volume-weighted price during the repurchase period [3]. Group 2: Compliance and Regulations - The buyback will comply with the EU's Market Abuse Regulation and adhere to the limitations set by shareholders at the annual general meeting held on June 12, 2025 [4].

Core Viewpoint - Fresenius Medical Care (FME) is accelerating its share buyback program, initiating the second tranche of a total EUR 1 billion buyback plan, with approximately EUR 415 million allocated for repurchase from January 12 to May 8, 2026 [1][8]. Group 1: Share Buyback Program - The first tranche of the share buyback program was completed ahead of schedule on December 29, 2025 [2]. - The total volume of the share buyback program is EUR 1 billion, and it is expected to be completed significantly earlier than originally planned, in less than a year [2][8]. - The second tranche is set to be executed by May 8, 2026 [8]. Group 2: Financial Performance and Strategy - The acceleration of the share buyback program is supported by strong financial performance and consistent execution of the 'FME Reignite' strategy, focusing on value creation and shareholder returns [3]. - Strong cash-flow generation, driven by continued business momentum, enables the acceleration of the share buyback program, showcasing the effectiveness of the new capital allocation framework [3]. Group 3: Company Overview - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving around 4.2 million patients worldwide who regularly undergo dialysis treatment [4]. - The company operates a network of 3,628 dialysis clinics, providing treatments for approximately 294,000 patients globally [4]. - Fresenius Medical Care is listed on both the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS) [4].

Core Viewpoint - U.S. defense companies face pressure from President Donald Trump, who has vowed to prevent them from paying dividends or repurchasing shares until they increase production levels [1] Group 1 - President Trump is demanding that defense companies accelerate their production to meet national security needs [1] - The pledge to block dividends and share buybacks indicates a significant shift in the relationship between the government and defense contractors [1]

Core Viewpoint - Shell anticipates higher oil and gas production but warns of a weak oil trading performance impacting earnings, amid declining prices [1] Group 1: Production and Trading Performance - Shell expects its fourth-quarter trading performance to be significantly lower than the previous quarter, leading to an adjusted loss in its chemicals-and-products division, down from a profit of $550 million in the prior quarter [2] - Analysts predict a 10% downward revision to Shell's net income expectations due to poor trading performance, contrasting with an improved performance in the previous quarter [6] Group 2: Market Conditions and Price Trends - The oil market is facing challenges with U.S. intervention in Venezuela potentially increasing supply in an already saturated market, contributing to weaker prices [4] - Despite geopolitical uncertainties, Brent crude prices remain just above $60 a barrel, and ExxonMobil has also indicated that falling oil and gas prices will negatively impact earnings [5] Group 3: Shareholder Returns and Financial Outlook - Shell's regular $3.5 billion quarterly share buyback is under scrutiny as analysts question whether management will maintain this amid a weak quarter, given the company's strong balance sheet [3] - Shell has narrowed its LNG production guidance for the fourth quarter to between 7.5 million and 7.9 million metric tons, tightening previous guidance [7]

Core Viewpoint - Wolters Kluwer has repurchased 120,013 ordinary shares for €10.8 million at an average price of €89.87 as part of its ongoing share buyback program, which aims to repurchase up to €200 million worth of shares by February 23, 2026 [2][3]. Share Buyback Program - The share buyback program was announced on November 5, 2025, with a total budget of €200 million for the period from November 6, 2025, to February 23, 2026 [3]. - As of January 7, 2026, the cumulative shares repurchased in 2026 amount to 120,013, with a total consideration of €10.8 million and an average share price of €89.87 [3]. Treasury Shares and Capital Reduction - Shares repurchased will be held as treasury shares and are intended for capital reduction through share cancellation [4]. Company Overview - Wolters Kluwer is a global leader in professional information solutions, software, and services, serving customers in over 180 countries and employing approximately 21,900 people [5][6]. - The company reported annual revenues of €5.9 billion for 2024 and is headquartered in Alphen aan den Rijn, the Netherlands [6].

Group 1 - Sampo plc conducted share buybacks on 7 January 2026, acquiring a total of 347,368 A shares at an average price of EUR 10.04 per share [1][2] - The share buyback program, announced on 5 November 2025, has a maximum limit of EUR 150 million and is in compliance with the Market Abuse Regulation [1] - The buyback program commenced on 6 November 2025, following authorization from Sampo's Annual General Meeting held on 23 April 2025 [1] Group 2 - After the recent transactions, Sampo plc now holds a total of 9,866,886 A shares, which represents 0.37% of the total number of shares in the company [2]